Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.58 |
| ▸ | RAB9A | P51151 | 11/20 | 0.58 |
| ▸ | NPC1 | O15118 | 10/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.58 |
| ▸ | TP53 | P04637 | 7/20 | 0.58 |
| ▸ | ESR1 | P03372 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490922 | 0.90 | MAPT (0.67) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL31410713 | 0.90 | ESR1 (0.66) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2245127 | 0.90 | ESR1 (0.66) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL1734740 | 0.87 | MAPT (0.68) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL1733986 | 0.84 | MAPT (0.57) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL25253936 | 0.84 | MAPT (0.59) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2489033 | 0.84 | MAPT (0.71) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2492941 | 0.84 | MAPT (0.72) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2245734 | 0.84 | RAB9A (0.56) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL20503687 | 0.82 | RAB9A (0.70) | MAPTRAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8330039-B2 | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| EP-2380208-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010085664-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100180947-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| EP-1954287-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | MAPT 1796/4885RAB9A 3929/4885NPC1 6/4885 |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | NFE2, NFE2L2, UBE2N | MAPT 1707/4885RAB9A 1343/4885NPC1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.